Publications

 

  1. Weinfurtner RJ, Ataya D, Funaro K, Abdalah M, Stringfield O, Raghunand N, Rosa M, Lee MC, Khakpour N, Laronga C, Kiluk J, Hoover S, Czerniecki B, Hogue D, Costa R, Armaghani A, Muller AS, Khong H, Soliman H, Han H. Quantitative Fractional Habitats Analysis of Triple Negative Breast Cancer on MRI Correlates with Pathologic Response to Combination Neoadjuvant Immuno/Chemo Therapy. (in review)
  2. Bryant JM, Stimphil E, Andre V, Shotbolt M, Zhang E, Estrella V, Husain K, Weygand J, Marchion D, Lopez AS, Abrahams D, Chen S, Abdel-Mottaleb M, Conlan S, Oraiqat I, Khatri V, Guevara JA, Pilon-Thomas S, Redler G, Latifi K, Raghunand N, Yamoah K, Hoffe S, Costello J, Frakes JM, Liang P, Khizroev S, Gatenby RA, Mokenge M. Theragnostic Irreversible Electroporation of Pancreatic Cancer Using MagnetoElectric NanoParticles. (in review)
  3. Fernando KRM, El Naqa I, Abdalah M, Ataya D, Bui MM, Brainerd JR, De La Cruz Y, Sobhani E, Stringfield O, Raghunand N, Niell BL. MRI-based Radiomics and Machine Learning for Predicting Upstaging Status in Ductal Carcinoma in Situ (DCIS). (in review)
  4. Pandey S, Kutuk T, Abdalah MA, Stringfield O, Ravi H, Mills MN, Graham JA, Latifi K, Moreno WA, Ahmed KA, Raghunand N. Prediction of Radiologic Outcome-Optimized Dose Plans and Post-Treatment Magnetic Resonance Images: a Proof-of-Concept Study in Breast Cancer Brain Metastases Treated with Stereotactic Radiosurgery. Physics and Imaging in Radiation Oncology 31:100602, 2024. (https://doi.org/10.1016/j.phro.2024.100602)
  5. Arias-Lorza AM, Costello JR, Hingorani SR, Von Hoff DD, Korn RL, Raghunand N. Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials. Scientific Reports 14, 11570 (2024). (https://doi.org/10.1038/s41598-024-62470-9)
  6. Mayfield J, Ataya D, Abdalah M, Stringfield O, Bui M, Raghunand N, Niell B, El Naqa I. Presurgical Upgrade Prediction of DCIS to Invasive Ductal Carcinoma Using Time-Dependent Deep Learning Models with DCE-MRI. Radiology: Artificial Intelligence 6(5):e230348, 2024. (doi: 10.1148/ryai.230348)
  7. Jeong DK, Morse B, Polk SL, Chen D-T, Li J, Hodul P, Centeno B, Costello J, Jiang K, Douaihi SM, El Naqa I, Farah PT, Huynh T, Raghunand N, Mok S, Dam A, Malafa M, Qayyum A, Fleming JB, Permuth JB. Pancreatic Cyst Size Measurement on Magnetic Resonance Imaging Compared to Pathology. Cancers 16(1):206, 2024. PMID: 38201633 (https://doi.org/10.3390/cancers16010206).
  8. Ravi H, Hawkins SH, Stringfield O, Pereira M, Chen D-T, Enderling H, Yu H-H, Arrington JA, Sahebjam S, Raghunand N. Rules-based Volumetric Segmentation of Multiparametric MRI for Response Assessment in Recurrent High-Grade Glioma. Res Sq [Preprint]. Res Sq [Preprint]. 2023 Sep 11: rs.3.rs-3318286. doi: 10.21203/rs.3.rs-3318286/v1. PMID: 37790451; PMCID: PMC10543497.
  9. Ravi H, Arias-Lorza AM, Costello JR, Han HS, Jeong DK, Klinz SG, Sachdev JC, Korn RL, Raghunand N. Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer. Radiology: Imaging Cancer 5(2):e220022, 2023 (doi: 10.1148/rycan.220022). See also Invited Commentary by Heike E. Daldrup-Link (doi: 10.1148/rycan.220183).
  10. Weinfurtner RJ, Abdalah M, Stringfield O, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Niell BL, Montejo M, Raghunand N. Quantitative Changes in Intratumoral Habitats on MRI Correlate with Pathologic Response in Early-Stage ER/PR+ HER2- Breast Cancer Treated with Preoperative Stereotactic Ablative Body Radiotherapy (SABR). Journal of Breast Imaging 4(3):273-284, 2022. (https://doi.org/10.1093/jbi/wbac013)
  11. Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clinical Breast Cancer 22(2):e214-e223, 2022. (doi: 10.1016/j.clbc.2021.06.016)
  12. Youssef I, Poch M, Raghunand N, Pow-Sang J, Johnstone P. Analysis of MRI Radiomic Pelvimetry and Correlation with Margin Status after Robotic Prostatectomy. The Canadian Journal of Urology 29(1):10976-10978, 2022.
  13. Pandey S, Snider AD, Moreno WA, Ravi H, Bilgin A, Raghunand N. Joint Total Variation-Based Reconstruction of Multiparametric Magnetic Resonance Images for Mapping Tissue Types. NMR in Biomedicine 34(12):e4597, 2021. (https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/nbm.4597)
  14. Raghunand N and Gatenby RA. “Bridging Spatial Scales from Radiographic Images to Cellular and Molecular Properties in Cancers”, Chapter 85, In: Molecular Imaging: Principles and Practice, 2nd edition, Editors: Ross & Gambhir, 2021. (https://www.sciencedirect.com/science/article/pii/B9780128163863000533)
  15. Kingsley JL, Costello JR, Raghunand N, Rejniak KA. Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations. PLOS Computational Biology 17(7):e1009206, 2021 (https://doi.org/10.1371/journal.pcbi.1009206).
  16. Niell BL, Abdalah M, Stringfield O, Raghunand N, Ataya D, Gillies RJ, Balagurunathan Y. Quantitative measures of background parenchymal enhancement predict breast cancer risk. American Journal of Roentgenology 217:64-75, 2021 (doi: 10.2214/AJR.20.23804).
  17. Mazin A, Hawkins SH, Stringfield O, Dhillon J, Manley BJ, Jeong DK, Raghunand N. Identification of Sarcomatoid De-Differentiation in Renal Cell Carcinoma by Machine Learning on Multiparametric MRI. Scientific Reports 11, 3785, 2021 (https://www.nature.com/articles/s41598-021-83271-4).
  18. Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko C, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HHM. Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study. Neuro-Oncology 23, 677-686, 2021 (doi: 10.1093/neuonc/noaa260).
  19. Hernandez-Prera JC, Valderrabano P, Creed J, De La Iglesia J, Slebos R, Centeno B, Tarasova V, Hallanger-Johnson J, Otto K, Veloski C, Wenig B, Yoder S, Lam CA, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and Ras Mutations. Thyroid 31:36-49, 2021.
  20. Arias Lorza AM, Ravi H, Philip RC, Galons JP, Trouard TP, Parra NA, Von Hoff DD, Read WL, Tibes R, Korn RL, Raghunand N. Dose-Response Assessment by Quantitative MRI in a Phase 1 Clinical Study of the Anti-Cancer Vascular Disrupting Agent Crolibulin. Scientific Reports 10, 14449, 2020 (https://www.nature.com/articles/s41598-020-71246-w).
  21. Glazar DJ, Grass GD, Arrington JA, Forsyth PA, Raghunand N, Yu HHM, Sahebjam S, Enderling H. Tumor volume dynamics as an early biomarker for patient-specific evolution of resistance and progression in recurrent high-grade glioma. J Clin. Med. 9:2019, 2020 (doi: 10.3390/jcm9072019).
  22. Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter A, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR. ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: a Multi-disciplinary Team-based, Multifactorial Analytical Approach. American J Clinical Oncology 42:655-661, 2019 (doi: 10.1097/COC.0000000000000564).
  23. Stringfield O, Arrington JA, Johnston SK, Rognin NG, Peeri NC, Balagurunathan Y, Jackson PR, Clark-Swanson KR, Swanson KR, Egan KM, Gatenby RA, Raghunand N. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme. Tomography 5:135-144, 2019 (doi: 10.18383/j.tom.2018.00052).
  24. Jeong DK, Raghunand N, Hernando D, Poch M, Jeong K, Eck B, Dhillon J. Quantification of sarcomatoid dedifferentiation in renal cell carcinoma on magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery 8:373-382, 2018 (doi: 10.21037/qims.2018.04.09).
  25. Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Magnetic Resonance Imaging of RRx-001 Pharmacodynamics in Preclinical Tumors. Oncotarget 8:102511-102520, 2017 (doi: 10.18632/oncotarget.18455).
  26. Ramanathan RK, Korn RL, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J, Hendriks BS, Drummond DC, Bayever E, Fitzgerald JB. Correlation Between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study. Clinical Cancer Res. 23:3638-3648, 2017 (doi: 10.1158/1078-0432.CCR-16-1990).
  27. Landowski TH, Guntle GP, Zhao D, Jagadish B, Mash EA, Dorr RT, Raghunand N. “Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model”, Translational Oncology 9:228-235, 2016 (doi: 10.1016/j.tranon.2016.04.007).
  28. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard M, Devoe CE. “Phase 1b Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer”, Clinical Cancer Res. 22:2848-2854, 2016 (doi: 10.1158/1078-0432.CCR-15-2010).
  29. Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD. “Phase II Trial of Vatalanib in Patients with Advanced or Metastatic Pancreatic Adenocarcinoma After First-line Gemcitabine Therapy (PCRT 04-001)”, Cancer Chemother. Pharmacol., 74:379-387, 2014 (doi: 10.1007/s00280-014-2499-4).
  30. Jagadish B, Ozumerzifon TJ, Roberts SA, Hall GB, Mash EA, Raghunand N. Improved Synthesis of 10-(2-Alkylamino-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic Acid Derivatives Bearing Acid-Sensitive Linkers, Synthetic Communications 44:441-449, 2014 (doi: 10.1080/00397911.2013.813547).
  31. Baker AF, Adab KN, Raghunand N, Chow HHS, Stratton S, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T. “A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers”, Investigational New Drugs 31:631-641, 2013 (doi: 10.1007/s10637-012-9846-2).
  32. Jagadish B, Guntle GP, Zhao D, Gokhale V, Ozumerzifon TJ, Ahad AM, Mash EA, Raghunand N. “Redox-active Magnetic Resonance Imaging Contrast Agents: Studies with Thiol-bearing 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic Acid Derivatives”, J Med. Chem. 55:10378-10386, 2012 (doi: 10.1021/jm300736f).
  33. Guntle GP, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N. “Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-bearing DOTA Complex of Gadolinium”, Translational Oncology 5:190-199, 2012 (doi: 10.1593/tlo.11322).
  34. Rajaraman S, Rodriguez JJ, Graff C, Altbach MI, Dragovich T, Sirlin CB, Korn RL, Raghunand N. “Automated Registration of Sequential Breath-Hold Dynamic Contrast-Enhanced MRI Images: a Comparison of 3 Techniques”, Magnetic Resonance Imaging 29:668-682, 2011 (doi: 10.1016/j.mri.2011.02.012).
  35. Jagadish B, Brickert-Albrecht GL, Nichol GS, Mash EA, Raghunand N. “On the synthesis of 1,4,7-Tris(tert- butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane”, Tetrahedron Letters 52:2058-2061, 2011 (doi: 10.1016/j.tetlet.2010.10.074).
  36. Raghunand N, Guntle GP, Gokhale V, Nichol G, Mash EA, Jagadish B. “Design, Synthesis, and Evaluation of 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic Acid-Derived, Redox-Sensitive Contrast Agents for Magnetic Resonance Imaging”, Journal of Medicinal Chemistry 53:6747-6757, 2010 (doi: 10.1021/jm100592u).
  37. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. “Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases”, Cancer Research 69:2260-2268, 2009 (doi: 10.1158/0008-5472.CAN-07-5575).
  38. Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C, Baggett B, Raghunand N, Gillies RJ. “Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway”, NMR in Biomedicine 22:114-127. 2009 (doi: 10.1002/nbm.1318).
  39. Jennings DL, Raghunand N, Gillies RJ. “Imaging Hemodynamics”, Cancer & Metastasis Reviews, 27:589-613, 2008 (doi: 10.1007/s10555-008-9157-4).
  40. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C, Gillies RJ. “Response of choline metabolites to docetaxel therapy is quantified in vivo by localized 31P MRS of human breast cancer xenografts and in vitro by high-resolution 31P NMR spectroscopy of cell extracts”, Magnetic Resonance in Medicine, 58:270-280, 2007 (doi: 10.1002/mrm.21333).
  41. Rajguru NS, Rodriguez JJ, Raghunand N, Gillies RJ. Enhanced Level-Set Approach to Segmentation of 3-D Heterogeneous Lesions from Dynamic Contrast-Enhanced MR Images, Image Analysis and Interpretation, 2006, DOI 10.1109/SSIAI.2006.1633724, 71-75, 2006.
  42. Raghunand N, Jagadish B, Trouard TP, Galons JP, Gillies RJ, Mash EA. “Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin”, Magnetic Resonance in Medicine, 55:1272-1280, 2006 (doi: 10.1002/mrm.20904).
  43. Raghunand N. “Tissue pH Measurement by Magnetic Resonance Spectroscopy and Imaging”, Chapter 14, pp 347-364, In: Methods in Molecular Medicine, Vol. 124, Magnetic Resonance Imaging: Methods and Biologic Applications, PV Prasad (Ed.), Humana Press Inc., Totowa, NJ, 2006 (doi: 10.1385/1-59745-010-3:347).
  44. Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. “High resolution pHe imaging of rat glioma using pH-dependent relaxivity”, Magnetic Resonance in Medicine, 55:309-315, 2006 (doi: 10.1002/mrm.20773).
  45. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. “Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1a using PX-478”, Neoplasia., 7:475-485, 2005 (doi: 10.1593/neo.04628).
  46. Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G, Baker AF. “The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging”, Clinical Cancer Research., 11:529-536, 2005.
  47. Gillies RJ, Raghunand N. “MRI/MRS to predict and monitor response to anticancer therapies”, In: Biomedical Magnetic Resonance: Proceedings of the International Workshop, NR Jagannathan (Ed.), 233-246. Jaypee Brothers Medical Publishers, New Delhi, 2004.
  48. Gillies RJ, Raghunand N, Garcia-Martin ML, Gatenby RA. “A review of pH measurement methods and applications in cancers”, IEEE Engineering in Medicine and Biology, 23:57-64, 2004 (doi: 10.1109/memb.2004.1360409).
  49. Raghunand N, Mahoney BP, Gillies RJ. “Tumor acidity, ion trapping and chemotherapeutics II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents”, Biochemical Pharmacology, 66:1219-1229, 2003 (doi: 10.1016/s0006-2952(03)00468-4).
  50. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. “Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro”, Biochemical Pharmacology, 66:1207-1218, 2003 (doi: 10.1016/s0006-2952(03)00467-2).
  51. Raghunand N, Howison CM, Zhang S, Sherry AD, Gillies RJ. “Renal and Systemic pH Imaging by Contrast-Enhanced MRI”, Magnetic Resonance in Medicine, 49:249-257, 2003 (doi: 10.1002/mrm.10347).
  52. Raghunand N, Gatenby RA, Gillies RJ. “Microenvironmental and Cellular Consequences of Altered Blood Flow in Tumors”, British Journal of Radiology, 76:S11-S22, 2003 (doi: 10.1259/bjr/12913493).
  53. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. “MRI of the Tumor Microenvironment”, Journal of Magnetic Resonance Imaging, 16:430-450, 2002 (doi: 10.1002/jmri.10181).
  54. Jennings D, Hatton BN, Guo J, Galons J-P, Trouard T, Raghunand N, Marshall J, Gillies RJ. “Early response of prostate carcinoma xenografts to Docetaxel chemotherapy monitored with diffusion MRI”, Neoplasia, 4:255-262, 2002 (doi: 10.1038/sj.neo.7900225).
  55. Raghunand N, Mahoney B, Van Sluis R, Baggett B, Gillies RJ. “Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak-base mitoxantrone”, Neoplasia, 3:227-235, 2001 (doi: 10.1038/sj.neo.7900151).
  56. Raghunand N, Gillies RJ. “pH and Chemotherapy”, In: The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity, JA Goode and DJ Chadwick (Eds.), Novartis Foundation Symposium 240:199-211, Wiley, Chichester, 2001 (doi: 10.1002/0470868716.ch14).
  57. Raghunand N, Gillies RJ. “pH and drug resistance in tumors”, Drug Resistance Updates, 3:39-47, 2000 (doi: 10.1054/drup.2000.0119).
  58. Gillies RJ, Raghunand N. “Nuclear Magnetic Resonance (NMR) Spectroscopy in the Study of Whole-Animal Metabolism”, In: Nature Encyclopedia of Life Sciences, http://www.els.net, London: Nature Publishing Group, 2000.
  59. Evelhoch J, Karczmar G, Koutcher J, Maxwell R, Nalcioglu O, Raghunand N, Ross B, Swartz H. “Applications of magnetic resonance in model systems: II. Cancer Therapeutics”, Neoplasia, 2:152-165, 2000 (doi: 10.1038/sj.neo.7900078).
  60. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. “Causes and effects of heterogeneous perfusion in tumors”, Neoplasia, 1:197-207, 1999 (doi: 10.1038/sj.neo.7900037).
  61. Raghunand N, He X, Van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murietta G, Roe D, Bhujwalla ZM, Gillies RJ. "Enhancement of chemotherapy by manipulation of tumor pH", British Journal of Cancer, 80:1005-1011, 1999 (doi: 10.1038/sj.bjc.6690455).
  62. Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ. " pH and drug resistance II: Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs", Biochemical Pharmacology, 57:1047-1058, 1999 (doi: 10.1016/s0006-2952(99)00021-0).
  63. Martinez-Zaguilan R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ. "pH and drug resistance I: Plasmalemmal V-type H+-ATPase is functionally expressed in drug resistant human breast carcinoma cell lines", Biochemical Pharmacology, 57:1037-1046, 1999 (doi: 10.1016/s0006-2952(99)00022-2).
  64. Van Sluis R, Bhujwalla ZM, Raghunand N, Ballesteros P, Alvarez J, Cerdan S, Galons J-P, Gillies RJ. "Imaging of extracellular pH using 1H MRSI", Magnetic Resonance in Medicine, 41:743-750, 1999 (doi: 10.1002/(sici)1522-2594(199904)41:4<743::aid-mrm13>3.0.co;2-z).
  65. Raghunand N, Altbach MI, Van Sluis R, Baggett B, Taylor CW, Bhujwalla ZM, Gillies RJ. "Plasmalemmal pH gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P MR Spectroscopy", Biochemical Pharmacology, 57:309-312, 1999 (doi: 10.1016/s0006-2952(98)00306-2).
  66. Raghunand, N, Dale BE. "Alteration of glucose consumption kinetics with progression of baculovirus infection in Spodoptera frugiperda cells", Applied Biochemistry and Biotechnology, 80:231-242, 1997 (doi: 10.1385/abab:80:3:231).
  67. Raghunand N, Dale BE. "Effects of glucose, glutamine and malate on the metabolism of Spodoptera frugiperda cells: an initial rate study", Applied Biochemistry and Biotechnology, 56:19-35, 1994 (https://doi.org/10.1007/BF02787867).
  68. Gillies RJ, Scherer PG, Raghunand N, Okerlund LS, Zaguilan RM, Hesterberg L, Dale BE. "Iteration of hybridoma growth and productivity in hollow fiber bioreactors using 31P-NMR", Magnetic Resonance in Medicine, 18:181-192, 1991 (doi: 10.1002/mrm.1910180118).
  69. Raghunand N, Thyagarajan S, Gopalakrishna K, Venkatram T. Treatment of starch wastes using a rotating biological contactor, Indian Chemical Engineer 32:11-16. 1990.